23904-94-1 Usage
Chemical structure
The compound is made up of a piperazine ring with additional substituents including a butyl group, a chlorophenyl group, a phenyl group, and a methylphenyl group.
Pharmacological applications
Piperazine derivatives are known to have various biological activities including antidepressant, anxiolytic, and antipsychotic effects.
Specific activity and potency
The presence of the butyl, chlorophenyl, phenyl, and methylphenyl substituents could potentially affect the compound's specific activity and potency.
Research and development
It is a valuable compound for further research and development in the pharmaceutical industry due to its potential therapeutic applications and unique chemical structure.
Molecular weight
The molecular weight of the piperazine compound is approximately 531.15 g/mol, and the molecular weight of the ethanedioate is approximately 90.03 g/mol.
Solubility
The solubility of the compound may vary depending on the solvent used, but it is likely to be more soluble in organic solvents such as ethanol or dimethyl sulfoxide (DMSO) due to its lipophilic nature.
Stability
The stability of the compound may be influenced by factors such as temperature, light exposure, and the presence of moisture or other reactive substances.
Synthesis
The compound can be synthesized through various chemical reactions, involving the formation of the piperazine ring and the subsequent introduction of the substituents.
Purity
The purity of the compound can be determined using techniques such as high-performance liquid chromatography (HPLC) or mass spectrometry.
Check Digit Verification of cas no
The CAS Registry Mumber 23904-94-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,9,0 and 4 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 23904-94:
(7*2)+(6*3)+(5*9)+(4*0)+(3*4)+(2*9)+(1*4)=111
111 % 10 = 1
So 23904-94-1 is a valid CAS Registry Number.
